Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi

References

• Rosenwald A, Wright G, Chan WC, et al The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937–1947.
   PubMed Web of Science ®Google Scholar
• Shipp MA, Harrington DP, Anderson JR, et al A predictive model for aggressive non-Hodgkins-lymphoma. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Miller TP, Dahlberg S, Cassady JR, et al Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:21–26.
   PubMed Web of Science ®Google Scholar
• Reyes F, Lepage E, Ganem G, et al ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005;352:1197–1205.
   PubMed Web of Science ®Google Scholar
• Shenkier TN, Voss N, Fairey R, et al Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 2002;20:197–204.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Ho AD, Cavallin-Stahl E, et al Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 2008;9:435–444.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117–4126.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, et al Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002–1006.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Cox D. Regression model and life-tables. J R Stat Soc Ser B 1972;34:187–220.
   Web of Science ®Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496–509.
   Web of Science ®Google Scholar
• Miller TP, Jones SE. Chemotherapy of localised histiocytic lymphoma. Lancet 1979;1:358–360.
   PubMed Web of Science ®Google Scholar
• Cabanillas F, Bodey GP, Freireich EJ. Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types. Cancer 1980;46:2356–2359.
   PubMed Web of Science ®Google Scholar
• Connors JM, Klimo P, Fairey RN, Voss N. Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann Intern Med 1987;107:25–30.
   PubMed Web of Science ®Google Scholar
• Federico M, Moretti G, Gobbi PG, et al ProMACE-cytaBOM versus MACOP-B in intermediate and high grade NHL. Preliminary results of a prospective randomized trial. Leukemia 1991;5(Suppl 1):95–101.
   PubMed Web of Science ®Google Scholar
• Carotenuto MF, Avanzini P, Baldini L, et al A multicenter randomized trial of two different proMACE-CytaBOM derived protocols in aggressive non-Hodgkin's lymphomas (NHL). A preliminary report. Leuk Lymphoma 1992;7:25–28.
   Google Scholar
• Silingardi V, Federico M, Cavanna L, et al ProMECE-CytaBOM vs. MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian Lymphoma Study Group (GISL). Leuk Lymphoma 1995;17:313–320.
   PubMed Web of Science ®Google Scholar
• Federico M, Clo V, Brugiatelli M, et al Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL. Haematologica 1998;83:800–811.
   PubMed Web of Science ®Google Scholar
• Persky DO, Unger JM, Spier CM, et al Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 2008;26:2258–2263.
   PubMed Web of Science ®Google Scholar
• Sacchi S, Marcheselli L, Bari A, et al Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study. Haematologica 2008;93:1335–1342.
   PubMed Web of Science ®Google Scholar
• Boehme V, Zeynalova S, Kloess M, et al Incidence and risk factors of central nervous system recurrence in aggressive lymphoma – a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007;18:149–157.
   PubMed Web of Science ®Google Scholar
• Bernstein SH, Unger JM, Leblanc M, et al Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 – the Southwest Oncology Group. J Clin Oncol 2009;27:114–119.
   PubMed Web of Science ®Google Scholar
• Iannitto E, Minardi V, Gobbi PG, et al Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial. Clin Lymphoma Myeloma 2009;9:138–144.
   PubMedGoogle Scholar
• Mikhaeel NG, Hutchings M, Fields PA, et al FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005;16:1514–1523.
   PubMed Web of Science ®Google Scholar
• Jhanwar YS, Straus DJ. The role of PET in lymphoma. J Nucl Med 2006;47:1326–1334.
   PubMed Web of Science ®Google Scholar
• Schot BW, Zijlstra JM, Sluiter WJ, et al Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 2007;109:486–491.
   PubMed Web of Science ®Google Scholar
• Sutcliffe SB. The curative role of radiation therapy in the management of patients with localized non-Hodgkin's lymphoma. Bull NY Acad Med 1987;63:168–180.
   PubMedGoogle Scholar
• Sutcliffe SB, Gospodarowicz MK, Bush RS, et al Role of radiation therapy in localized non-Hodgkin's lymphoma. Radiother Oncol 1985;4:211–223.
   PubMed Web of Science ®Google Scholar
• Longo DL. Combined modality therapy for localized aggressive lymphoma: enough or too much? J Clin Oncol 1989;7:1179–1181.
   PubMed Web of Science ®Google Scholar
• Kodaira T, Fuwa N, Kamata M, et al Single institute experience of chemotherapy and adjuvant radiotherapy for localized aggressive non-Hodgkin's lymphoma: retrospective analysis of the clinical efficacy of radiation therapy. Am J Clin Oncol 2002;25:612–618.
   PubMed Web of Science ®Google Scholar
• D'Orazio A, Johnson L. In: 44th annual meeting of the American Society of Hematology. December 7–10, 2002: Philadelphia, Pennsylvania. Short-course chemotherapy without radiation therapy could be sufficient for elderly patients with localized aggressive non-Hodgkin's lymphoma. Clin Lymphoma 2003;3:203–208.
   PubMedGoogle Scholar
• Ng AK, Mauch PM. Role of radiation therapy in localized aggressive lymphoma. J Clin Oncol 2007;25:757–759.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M, et al Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027–5033.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, et al CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Trneny M, Rieger M, Osterborg A, et al The addition of rituximab eliminates the negative prognostic impact of PMBCL compared to DLBCL in young patients with CD20-positive aggressive lymphomas receiving a CHOP-like chemotherapy: results of a subgroup analysis of the Mabthera International Trial Group (MInT) study. Blood 2008;112:311.
   Web of Science ®Google Scholar
• Martelli M, Stefoni V, Russo E, et al Rituximab does not improve survival of patients treated with M/Vacop-B plus radiotherapy in primary mediastinal large B-cell lymphoma (Pmlbcl): a phase ii study of Inter-Gruppo Italiano Linfomi (IIL). Haematologica 2008;93:309.
   PubMed Web of Science ®Google Scholar